Sol-Gel Technologies

OverviewSuggest Edit

Sol-Gel Technologies is engaged in the development of a range of specialty pharmaceuticals. The Company designs and delivers innovative dermatological drugs ranging from completely non-leachable to highly-controlled-release of unique formulations and compounds.
TypePublic
Founded1997
HQNess Ziona, IL
Websitesol-gel.com

Latest Updates

Employees (est.) (Dec 2018)56(+15%)
Share Price (Oct 2020)$8
Cybersecurity ratingAMore

Key People/Management at Sol-Gel Technologies

Moshe Arkin

Moshe Arkin

Chairman of Our Board of Directors
Alon Seri-Levy

Alon Seri-Levy

Co-Founder and Chief Executive Officer, Director
Gilad Mamlok

Gilad Mamlok

CFO
Ofer Toledano

Ofer Toledano

VP Research and Development
Itai Arkin

Itai Arkin

Director
Ofra Levy-Hacham

Ofra Levy-Hacham

VP Clinical and Regulatory Affairs
Show more

Sol-Gel Technologies Office Locations

Sol-Gel Technologies has an office in Ness Ziona
Ness Ziona, IL (HQ)
7 Golda Me'ir St
Show all (1)

Sol-Gel Technologies Financials and Metrics

Sol-Gel Technologies Revenue

Market capitalization (29-Oct-2020)

184.9m

Closing stock price (29-Oct-2020)

8.0
Sol-Gel Technologies's current market capitalization is $184.9 m.
Show all financial metrics

Sol-Gel Technologies Cybersecurity Score

Cybersecurity ratingPremium dataset

A

97/100

SecurityScorecard logo

Sol-Gel Technologies Online and Social Media Presence

Embed Graph

Sol-Gel Technologies News and Updates

Sol-Gel Technologies Reports Second Quarter 2020 Financial Results and Corporate Update

NESS ZIONA, Israel, Aug. 06, 2020 (GLOBE NEWSWIRE) -- Sol-Gel Technologies, Ltd. (NASDAQ: SLGL), a clinical-stage dermatology company focused on identifying, developing and commercializing branded and generic topical drug products for the treatment of skin diseases, today announced financial resul…

Sol-Gel Technologies Partnered Generic Product Expected to Launch in the Second Quarter of 2021

NESS ZIONA, Israel, July 28, 2020 (GLOBE NEWSWIRE) -- Sol-Gel Technologies, Ltd. (NASDAQ: SLGL), a clinical-stage dermatology company focused on identifying, developing and commercializing branded and generic topical drug products for the treatment of skin diseases, today announced that Sol-Gel ha…

Sol-Gel Technologies Announces Closing of Additional $5.0 Million Investment

Investment is for ordinary shares and warrants to purchase ordinary shares at a combined price of $11 per ordinary share and accompanying warrants to purchase 0.80 of an ordinary share

Sol-Gel Technologies to Present at Upcoming 2020 Solebury Trout Virtual Investor Conference

NESS ZIONA, Israel, March 25, 2020 (GLOBE NEWSWIRE) -- Sol-Gel Technologies, Ltd. (NASDAQ: SLGL) (“Sol-Gel” or the “Company”), a clinical-stage dermatology company focused on identifying, developing and commercializing branded and generic topical drug products for the treatment of skin diseases, t…

Sol-Gel Technologies Reports Third Quarter 2019 Financial Results and Corporate Update

NESS ZIONA, Israel, Nov. 13, 2019 (GLOBE NEWSWIRE) -- Sol-Gel Technologies, Ltd. (NASDAQ: SLGL), a clinical-stage dermatology company focused on identifying, developing and commercializing branded and generic topical drug products for the treatment of skin diseases, today announced financial resul…

Sol-Gel Technologies reports positive results in trials of treatment for papulopustular rosacea

Sol-Gel Technologies Ltd. said Monday that two late-stage trials of a treatment for papulopustular rosacea produced positive results. The Israeli company said the trials evaluating Epsolay(R) microencapsulated benzoyl peroxide cream, 5%, made with the company's proprietary microencapsulation techno…
Show more

Sol-Gel Technologies Blogs

Sol-Gel Technologies Reports First Quarter 2020 Financial Results and Corporate Update

New Drug Applications for Epsolay® and Twyneo® remain on track for the second quarter and second half 2020, respectively Completed a $23 million underwritten public offering in February with an additional $5 million investment from Sol-Gel’s controlling shareholder in April, providing cash runway

Sol-Gel Technologies to Report First Quarter 2020 Financial Results and Company Updates on May 14, 2020

NESS ZIONA, Israel , May 07, 2020 (GLOBE NEWSWIRE) -- Sol-Gel Technologies, Ltd. (NASDAQ: SLGL) (“Sol-Gel” or the “Company”), a clinical-stage dermatology company focused on identifying, developing and commercializing branded and generic topical drug products for the treatment of skin diseases,

Sol-Gel Technologies Reports Full Year 2019 Financial Results and Corporate Update

Sol-Gel Technologies Reports Full Year 2019 Financial Results and Corporate Update Content Import Tue, 03/24/2020 - 16:05 Sol-Gel Technologies Reports Full Year 2019 Financial Results and Corporate Update March 24, 2020 at 4:05 PM EDT This release is a backfil…

Sol-Gel Technologies to Report Full Year 2019 Financial Results and Corporate Update

NESS ZIONA, Israel , March 19, 2020 (GLOBE NEWSWIRE) -- Sol-Gel Technologies, Ltd. (NASDAQ: SLGL) (“Sol-Gel” or the “Company”), a clinical-stage dermatology company focused on identifying, developing and commercializing branded and generic topical drug products for the treatment of skin diseases,

Sol-Gel Announces Positive Topline Results from Open-Label, Long-Term Safety Study of Epsolay® for Treatment up to 52 Weeks

Sol-Gel Announces Positive Topline Results from Open-Label, Long-Term Safety Study of Epsolay® for Treatment up to 52 Weeks Content Import Thu, 02/13/2020 - 16:06 Sol-Gel Announces Positive Topline Results from Open-Label, Long-Term Safety Study of Epsolay® for Treatment up to 52 Weeks …

Sol-Gel Provides Product Pipeline Updates and Anticipated Milestones for 2020

Sol-Gel Provides Product Pipeline Updates and Anticipated Milestones for 2020 Content Import Wed, 02/05/2020 - 07:05 Sol-Gel Provides Product Pipeline Updates and Anticipated Milestones for 2020 February 5, 2020 at 7:05 AM EST This release is a backfill from a…
Show more

Sol-Gel Technologies Frequently Asked Questions

  • When was Sol-Gel Technologies founded?

    Sol-Gel Technologies was founded in 1997.

  • Who are Sol-Gel Technologies key executives?

    Sol-Gel Technologies's key executives are Moshe Arkin, Alon Seri-Levy and Gilad Mamlok.

  • How many employees does Sol-Gel Technologies have?

    Sol-Gel Technologies has 56 employees.

  • Who are Sol-Gel Technologies competitors?

    Competitors of Sol-Gel Technologies include dMed, Vifor Pharma and Alentis Therapeutics.

  • Where is Sol-Gel Technologies headquarters?

    Sol-Gel Technologies headquarters is located at 7 Golda Me'ir St, Ness Ziona.

  • Where are Sol-Gel Technologies offices?

    Sol-Gel Technologies has an office in Ness Ziona.

  • How many offices does Sol-Gel Technologies have?

    Sol-Gel Technologies has 1 office.